Nextage Therapeutics (Israel) Today

MCTC Stock  ILA 81.00  1.90  2.29%   

Performance

6 of 100

 
Weak
 
Strong
Modest

Odds Of Distress

Less than 44

 
High
 
Low
Below Average
Nextage Therapeutics is trading at 81.00 as of the 23rd of November 2024, a 2.29 percent decrease since the beginning of the trading day. The stock's open price was 82.9. Nextage Therapeutics has about a 44 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Nextage Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of December 2023 and ending today, the 23rd of November 2024. Click here to learn more.
Micromedic Technologies Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. MICROMEDIC TECHNOL operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange.. The company has 2.27 M outstanding shares. More on Nextage Therapeutics

Moving together with Nextage Stock

  0.68ALRPR Alrov Properties LodgingsPairCorr

Moving against Nextage Stock

  0.46DANH Dan Hotels Earnings Call This WeekPairCorr
  0.46AVRT Avrot IndustriesPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Nextage Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Nextage Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Nextage Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Chief Executive OfficerMeir Yoeli
Business ConcentrationHealth Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Nextage Therapeutics (MCTC) is traded on Tel Aviv Stock Exchange in Israel and employs 6 people. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.54 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nextage Therapeutics's market, we take the total number of its shares issued and multiply it by Nextage Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Nextage Therapeutics operates under Biotechnology sector and is part of Health Care industry. The entity has 2.27 M outstanding shares. Nextage Therapeutics has accumulated about 358 K in cash with (5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16.
Check Nextage Therapeutics Probability Of Bankruptcy
Ownership Allocation
Nextage Therapeutics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months.
Check Nextage Ownership Details

Nextage Therapeutics Risk Profiles

Although Nextage Therapeutics' alpha and beta are two of the key measurements used to evaluate Nextage Therapeutics' performance over the market, the standard measures of volatility play an important role as well.

Nextage Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in Nextage Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run FinTech Suite Now

   

FinTech Suite

Use AI to screen and filter profitable investment opportunities
All  Next Launch Module

Other Information on Investing in Nextage Stock

Nextage Therapeutics financial ratios help investors to determine whether Nextage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nextage with respect to the benefits of owning Nextage Therapeutics security.